{
    "organizations": [],
    "uuid": "e8a03b08c68bd75f78d29e688d8ba9eb52c7edd3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-oncolytics-biotech-receives-specia/brief-oncolytics-biotech-receives-special-protocol-assessment-agreement-from-fda-for-phase-3-clinical-trial-of-pelareorep-in-metastatic-breast-cancer-idUSASC0A1CG",
    "ord_in_thread": 0,
    "title": "BRIEF-Oncolytics Biotech Receives Special Protocol Assessment Agreement From FDA For Phase 3 Clinical Trial Of Pelareorep In Metastatic Breast Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - Oncolytics Biotech Inc:\n* ONCOLYTICS BIOTECHÂ® RECEIVES SPECIAL PROTOCOL ASSESSMENT AGREEMENT FROM FDA FOR PHASE 3 CLINICAL TRIAL OF PELAREOREP IN METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-10T19:13:00.000+03:00",
    "crawled": "2018-05-11T13:04:30.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "oncolytics",
        "biotech",
        "inc",
        "oncolytics",
        "receives",
        "special",
        "protocol",
        "assessment",
        "agreement",
        "fda",
        "phase",
        "clinical",
        "trial",
        "pelareorep",
        "metastatic",
        "breast",
        "cancer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}